Skip to main content
SpringerLink
Log in
Book cover

Hodgkin Lymphoma pp 141–161Cite as

Principles of Chemotherapy in Hodgkin Lymphoma

  • Chapter
  • First Online:

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

Abstract

Hodgkin lymphoma (HL) was perhaps the disease for which the possibility of cure with combination chemotherapy in the majority of patients was first realized. As such, it has provided a model upon which studies in many other types of malignancy have been based, and it is interesting to follow the trajectory of knowledge from early single-agent work through combinations, combined modalities, increasing complexity, and most recently, selective de-escalation. Patients with advanced disease represent a minority of those affected by HL. However, these patients represent the group in which the development and effects of chemotherapy are most readily appreciated, since the role of radiation therapy is markedly less than in those with localized disease. Historically, chemotherapy and radiotherapy contended for primacy in the management of this illness, a tension which persisted until the mid-1970s.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   199.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Peters MV. A study of survivals in Hodgkin’s disease treated radiologically. Am J Roentgenol. 1950;63:299–311.

    Google Scholar 

  2. Easson EC, Russel MH. The cure of Hodgkin’s disease. Br Med J. 1963;1:1704–7.

    Article  PubMed  CAS  Google Scholar 

  3. Kaplan HS. Clinical evaluation and radiotherapeutic management of Hodgkin’s disease and the malignant lymphomas. N Engl J Med. 1968;278(16):892–9.

    Article  PubMed  CAS  Google Scholar 

  4. Papac RJ. Origins of cancer therapy. Yale J Biol Med. 2001;74:191–8.

    Google Scholar 

  5. Goodman LS, Wintrobe MM, et al. Nitrogen mustard therapy. Use of methyl bis (B-chloroethyl) amine hydrochloride and tris (B-chloroethyl) amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia, certain allied and miscellaneous disorders. JAMA. 1946;132:126–32.

    Article  CAS  Google Scholar 

  6. Zubrod CG. Historic milestones in curative chemotherapy. Semin Oncol. 1979;6:490–505.

    PubMed  CAS  Google Scholar 

  7. Gross R, Lambers K. Erste erfarhungen in der Behandlung malignen tumoren mit einem neuen N-lost phosphamidester. Dtsch Med Wschr. 1958;83:458–62.

    Article  PubMed  CAS  Google Scholar 

  8. Burchenal JH. From wild fowl to stalking horses: alchemy in chemotherapy. Cancer. 1975;35:1121–35.

    Article  PubMed  CAS  Google Scholar 

  9. Mathe G, Cattan A, et al. Experimental therapeutic trials of leukemia and hematosarcomas: technologic and philosophic aspects. Ann N Y Acad Sci. 1969;164(3):776–92.

    Article  PubMed  CAS  Google Scholar 

  10. Rotolo V. Vincaleukoblastine in the therapy of malignant neoplasms. Friuli Med. 1968;23(1):31–52.

    PubMed  CAS  Google Scholar 

  11. Gilman A. The initial clinical trial of nitrogen mustard. Am J Surg. 1963;105(574):578.

    Google Scholar 

  12. Wagener DJT. The development of chemotherapy. In: The history of oncology. Berlin: Springer; 2009. p. 145–80.

    Google Scholar 

  13. Mathe G, Schweisguth O, et al. Value of vincaleukoblastine in the treatment of Hodgkin’s disease and other hematosarcomas and leukemias. Sem Ther. 1964;40(5):320–4.

    PubMed  CAS  Google Scholar 

  14. Tubiana M, Henry-Amar M, et al. Long-term results of the E.O.R.T.C. randomized study of irradiation and vinblastine in clinical stages I and II of Hodgkin’s disease. Eur J Cancer. 1979;15(5):645–57.

    PubMed  CAS  Google Scholar 

  15. Rosenberg SA, Kaplan HS. Evidence for an orderly progression in the spread of Hodgkin’s disease. Cancer Res. 1966;26(6):1225–31.

    PubMed  CAS  Google Scholar 

  16. Tubiana M, Hayat M, et al. Five-year results of the E.O.R.T.C. randomized study of splenectomy and spleen irradiation in clinical stages I and II of Hodgkin’s disease. Eur J Cancer. 1981;17(3):355–63.

    PubMed  CAS  Google Scholar 

  17. Bergsagel DE, Alison RE, et al. Results of treating Hodgkin’s disease without a policy of laparotomy staging. Cancer Treat Rep. 1982;66:717–31.

    PubMed  CAS  Google Scholar 

  18. Selby P, McElwain TJ, et al. Chemotherapy for Hodgkin’s disease. Section I: MOPP and its variants. In: Selby P, McElwain TJ, editors. Hodgkin’s disease. Oxford: Blackwell; 1987.

    Google Scholar 

  19. DeVita Jr VT et al. Principles of chemotherapy. In: DeVita Jr VT, editor. Cancer: principles and practice of oncology. 3rd ed. Philadelphia: J.B. Lipincott Company; 1989. p. 276–300.

    Google Scholar 

  20. Skipper HE, Schabel FM, et al. Experimental evaluation of potential anti-cancer agents. XII. On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemother Rep. 1964;35:1–111.

    PubMed  CAS  Google Scholar 

  21. Bonadonna G, Monfardini S, et al. Comparative effects of vinblastine and procarbazine in advanced Hodgkin’s disease. Eur J Cancer. 1969;5(4):393–402.

    PubMed  CAS  Google Scholar 

  22. Coltman CA. Chemotherapy of advanced Hodgkin’s disease. Semin Oncol. 1980;7:155–73.

    PubMed  Google Scholar 

  23. Bernard J. Current general principles of the treatment of Hodgkin’s disease, lymphosarcoma and reticulosarcoma. Rev Prat. 1966;16(7):871–9.

    PubMed  CAS  Google Scholar 

  24. DeVita Jr VT, Carbone PP. Treatment of Hodgkin’s disease. Med Ann Dist Columbia. 1967;36(4):232–4.

    PubMed  Google Scholar 

  25. DeVita VT, Serpick AA, et al. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970;73(6):881–95.

    PubMed  Google Scholar 

  26. DeVita VT, Simon RM, et al. Curability of advanced Hodgkin’s disease with chemotherapy. Ann Intern Med. 1980;92(5):587–95.

    PubMed  Google Scholar 

  27. Longo DL, Young RC, et al. Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol. 1986;4(9):1295–306.

    PubMed  CAS  Google Scholar 

  28. Canellos GP, Anderson JR, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478–84.

    Article  PubMed  CAS  Google Scholar 

  29. Carde P, MacKintosh FR, et al. A dose and time response analysis of the treatment of Hodgkin’s disease with MOPP chemotherapy. J Clin Oncol. 1983;1(2):146–53.

    PubMed  CAS  Google Scholar 

  30. Frei III E, Luce JK, et al. Combination chemotherapy in advanced Hodgkin’s disease: induction and maintenance of remission. Ann Intern Med. 1973;79(3):376–82.

    PubMed  Google Scholar 

  31. Somers R, Carde P, et al. A randomized study in stage IIIB and IV Hodgkin’s disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol. 1994;12(2):279–87.

    PubMed  CAS  Google Scholar 

  32. Carde P, Hayat M, et al. Comparison of total nodal irradiation versus combined sequence of mantle irradiation with mechlorethamine, vincristine, procarbazine, and prednisone in clinical stages I and II Hodgkin’s disease: experience of the European Organization for Research and Treatment of Cancer. NCI Monogr. 1988;(6):303–10.

    Google Scholar 

  33. Young RC, Chabner BA, et al. Maintenance chemotherapy for advanced Hodgkin’s disease in remission. Lancet. 1973;301(7816):1339–43.

    Article  Google Scholar 

  34. Lowenbraun STAN, DeVita VT, et al. Combination chemotherapy with nitrogen mustard, vincristine, procarbazine and prednisone in previously treated patients with Hodgkin’s disease. Blood. 1970;36(6):704–17.

    PubMed  CAS  Google Scholar 

  35. Fisher RI, DeVita VT, et al. Prolonged disease-free survival in Hodgkin’s disease with MOPP reinduction after first relapse. Ann Intern Med. 1979;90(5):761–3.

    PubMed  CAS  Google Scholar 

  36. Arseneau JC, Sponzo RW, et al. Non lymphomatous malignant tumors complicating Hodgkin’s disease: possible association with intensive therapy. N Engl J Med. 1972;287(22):1119–22.

    Article  PubMed  CAS  Google Scholar 

  37. Weiden PL, Lerner KG, et al. Pancytopenia and leukemia in Hodgkin’s disease: report of three cases. Blood. 1973;42(4):571–7.

    PubMed  CAS  Google Scholar 

  38. Sherins RJ, DeVita Jr VT. Effect of drug treatment for lymphoma on male reproductive capacity. Studies of men in remission after therapy. Ann Intern Med. 1973;79(2):216–20.

    PubMed  CAS  Google Scholar 

  39. Corder MP, Young RC, et al. Phytohemagglutinin-induced lymphocyte transformation: the relationship to prognosis of Hodgkin’s disease. Blood. 1972;39(5):595–601.

    PubMed  CAS  Google Scholar 

  40. Crowther D, Wagstaff J, et al. A randomized study comparing chemotherapy alone with chemotherapy followed by radiotherapy in patients with pathologically staged IIIA Hodgkin’s disease. J Clin Oncol. 1984;2(8):892–7.

    PubMed  CAS  Google Scholar 

  41. Nicholson WM, Beard ME, et al. Combination chemotherapy in generalized Hodgkin’s disease. Br Med J. 1970;3(713):7–10.

    Article  PubMed  CAS  Google Scholar 

  42. Ranson MR, Radford JA, et al. An analysis of prognostic factors in stage III and IV Hodgkin’s disease treated at a single centre with MVPP. Ann Oncol. 1991;2(6):83–9.

    Google Scholar 

  43. Dady PJ, McElwain TJ, et al. Five years’ experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin’s disease CHLVPP advanced HL. Br J Cancer. 1982;45:851–9.

    Article  PubMed  CAS  Google Scholar 

  44. McElwain TJ, Toy J, et al. A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin’s disease. Br J Cancer. 1977;36(276):280.

    Google Scholar 

  45. Luce JK, Gamble JF, et al. Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma. Cancer. 1971;28(2):306–17.

    Article  PubMed  CAS  Google Scholar 

  46. Bonadonna G, Monfardini S. Cardiac toxicity of daunorubicin. Lancet. 1969;1(7599):837.

    Article  PubMed  CAS  Google Scholar 

  47. Frei E, Luce JK, et al. 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of lymphoma. Cancer Treat Rep. 1972;56(5):667–70.

    Google Scholar 

  48. O’Bryan RM, Luce JK, et al. Phase II evaluation of adriamycin in human neoplasia. Cancer. 1973;32(1):1–8.

    Article  PubMed  Google Scholar 

  49. Bonadonna G, Zucali R, et al. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36(1):252–9.

    Article  PubMed  CAS  Google Scholar 

  50. Boleti E, Mead GM. ABVD for Hodgkin’s lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol. 2007;18(2):376–80.

    Article  PubMed  CAS  Google Scholar 

  51. Bonadonna G, Santoro A, et al. Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin’s disease: rationale, background studies, and recent results. Cancer Treat Rep. 1982;66(4):881–7.

    PubMed  CAS  Google Scholar 

  52. Goldie JH, Coldman AJ. Analyzing the patterns of treatment failure. J Clin Oncol. 1986;4(6):825–6.

    PubMed  CAS  Google Scholar 

  53. Santoro A, Bonadonna G, et al. Alternating drug combinations in the treatment of advanced Hodgkin’s disease. N Engl J Med. 1982;306(13):770–5.

    Article  PubMed  CAS  Google Scholar 

  54. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin’s disease trial. N Engl J Med. 2002;346(18):1417–8.

    Article  PubMed  Google Scholar 

  55. Aleman BM, Raemaekers JM, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med. 2003;348(24):2396–406.

    Article  PubMed  Google Scholar 

  56. Klimo P, Connors JM. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin’s disease. J Clin Oncol. 1985;3(9):1174–82.

    PubMed  CAS  Google Scholar 

  57. Radford JA, Crowther D, et al. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin’s disease. J Clin Oncol. 1995;13(9):2379–85.

    PubMed  CAS  Google Scholar 

  58. Sieber M, Tesch H, et al. Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s Lymphoma Study Group HD6 trial. Ann Oncol. 2004;15(2):276–82.

    Article  PubMed  CAS  Google Scholar 

  59. Duggan DB, Petroni GR, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol. 2003;21(4):607–14.

    Article  PubMed  CAS  Google Scholar 

  60. Johnson PWM, Radford JA, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin’s lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol. 2005;23(36):9208–18.

    Article  PubMed  CAS  Google Scholar 

  61. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep. 1977;61:1307–17.

    PubMed  CAS  Google Scholar 

  62. Diehl V, Franklin J, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348(24):2386–95.

    Article  PubMed  CAS  Google Scholar 

  63. Linch DC, Winfield D, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051–4.

    Article  PubMed  CAS  Google Scholar 

  64. Schmitz N, Pfistner B, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–71.

    Article  PubMed  CAS  Google Scholar 

  65. Hasenclever D, Brosteanu O, et al. Modelling of chemotherapy: the effective dose approach. Ann Hematol. 2001;80 Suppl 3:B89–94.

    PubMed  CAS  Google Scholar 

  66. Hasenclever D, Loeffler M, et al. German Hodgkin’s Lymphoma Study Group. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin’s disease. Ann Oncol. 1996;7(Suppl 4): 95–8.

    Google Scholar 

  67. Owadally WS, Sydes MR, et al. Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). Ann Oncol. 2010;21:568–73.

    Article  PubMed  CAS  Google Scholar 

  68. Brosteanu O, Hasenclever D, et al. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin’s disease. Ann Hematol. 2004;83(3):176–82.

    Article  PubMed  CAS  Google Scholar 

  69. Ribrag V, Koscielny S, et al. Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood. 2009;113(14):3307–13.

    Article  PubMed  CAS  Google Scholar 

  70. Henry-Amar M, Hayat M, et al. EORTC Lymphoma Cooperative Group. Causes of death after therapy for early stage Hodgkin’s disease entered on EORTC protocols. Int J Radiat Oncol Biol Phys. 1990;19(5):1155–7.

    Google Scholar 

  71. Van Leeuwen FE, Klokman WJ, et al. Second cancer risk following Hodgkin’s-disease – a 20-year follow-up-study. J Clin Oncol. 1994;12(2):312–25.

    PubMed  Google Scholar 

  72. Engert A, Diehl V, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548–54.

    Article  PubMed  Google Scholar 

  73. Engert A, Diehl V, et al. Two cycles of ABVD followed by involved field radiotherapy with 20 Gray (Gy) is the new standard of care in the treatment of patients with early-stage Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group (GHSG) HD10. Study supported by the Deutsche Krebshilfe and in part by the Competence Network Malignant Lymphoma. ASH Annu Meet Abstr. 2009;114(22):716.

    Google Scholar 

  74. Bartlett NL, Rosenberg SA, et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin’s disease: a preliminary report. J Clin Oncol. 1995;13(5):1080–8.

    PubMed  CAS  Google Scholar 

  75. Horning SJ, Williams J, et al. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin’s disease: Eastern Cooperative Oncology Group Pilot Study E1492. J Clin Oncol. 2000;18(5):972.

    PubMed  CAS  Google Scholar 

  76. Horning SJ, Hoppe RT, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20(3):630–7.

    Article  PubMed  Google Scholar 

  77. Gobbi PG, Levis A, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma: final results of a Multicenter Randomized Trial by the Intergruppo Italiano Linfomi. J Clin Oncol. 2005;23(36):9198–207.

    Article  PubMed  CAS  Google Scholar 

  78. Hoskin PJ, Lowry L, et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin’s lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol. 2009;27(32):5390–6.

    Article  PubMed  Google Scholar 

  79. Radford JA, Rohatiner AZS, et al. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin’s disease. J Clin Oncol. 2002;20(13):2988–94.

    Article  PubMed  CAS  Google Scholar 

  80. Green JA, Dawson AA, et al. Measurement of drug dosage intensity in MVPP therapy in Hodgkin’s disease. Br J Clin Pharmacol. 1980;9:511–4.

    Article  PubMed  CAS  Google Scholar 

  81. Diehl V, Sieber M, et al.; The German Hodgkin’s Lymphoma Study Group. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin’s disease. Ann Oncol. 1997;8(2):143–8.

    Google Scholar 

  82. Diehl V, Haverkamp H, et al. Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma (HL): final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG). ASCO Meet Abstr. 2009;27(15S):8544.

    Google Scholar 

  83. Engert A, Franklin J, et al. HD12 randomised trial comparing 8 dose-escalated cycles of BEACOPP with 4 escalated and 4 baseline cycles in patients with advanced stage Hodgkin lymphoma (HL): an analysis of the German Hodgkin Lymphoma Study Group (GHSG), University of Cologne, D-50924 Cologne, Germany. ASH Annu Meet Abstr. 2006;108(11):99.

    Google Scholar 

  84. Kobe C, Dietlein M, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood. 2008;112(10):3989–94.

    Article  PubMed  CAS  Google Scholar 

  85. Federico M, Luminari S, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009;27(5):805–11.

    Article  PubMed  Google Scholar 

  86. Gianni AM, Rambaldi A, et al. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): a randomized trial of the Michelangelo, GITIL and IIL cooperative groups. ASCO Meet Abstr. 2008;26(15 Suppl):8506.

    Google Scholar 

  87. Proctor SJ, Mackie M, et al. A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin’s disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index: a Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer. 2002;38(6):795–806.

    Article  PubMed  CAS  Google Scholar 

  88. Federico M, Bellei M, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy. J Clin Oncol. 2003;21(12):2320–5.

    Article  PubMed  CAS  Google Scholar 

  89. Arakelyan N, Berthou C, et al. Radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation five-year results of a randomized trial on behalf of the GOELAMS group. Cancer. 2008;113(12):3323–30.

    Article  PubMed  CAS  Google Scholar 

  90. Young RC, Canellos GP, et al. Patterns of relapse in advanced Hodgkin’s disease treated with combination chemotherapy. Cancer. 1978;42:1001–7.

    Article  PubMed  CAS  Google Scholar 

  91. Loeffler M, Brosteanu O, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International Database on Hodgkin’s Disease Overview Study Group. J Clin Oncol. 1998;16(3):818–29.

    PubMed  CAS  Google Scholar 

  92. Johnson PWM, Sydes MR, Hancock BW, Cullen MH, Radford JA, Stenning SP. Consolidation radiotherapy in patients with advanced Hodgkin lymphoma: survival data from the UKLG LY09 randomised controlled trial (ISRCTN97144519). Journal of Clinical Oncology. 2010;in press.

    Google Scholar 

  93. Diehl V, Loeffler M, et al. German Hodgkins’ Study Group (GHSG). Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin’s disease. Ann Oncol. 1995;6(9):901–10.

    Google Scholar 

  94. Ferme C, Sebban C, et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin’s disease: results of the Groupe d’etudes des Lymphomes de l’Adulte H89 trial. Blood. 2000;95(7):2246–52.

    PubMed  CAS  Google Scholar 

  95. Bonadonna G, Bonfante V, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol. 2004;22(14):2835–41.

    Article  PubMed  Google Scholar 

  96. Engert A, Franklin J, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007;25(23):3495–502.

    Article  PubMed  CAS  Google Scholar 

  97. Ferme C, Eghbali H, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med. 2007;357(19):1916–27.

    Article  PubMed  CAS  Google Scholar 

  98. Noordijk EM, Carde P, et al. Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol. 2006;24(19):3128–35.

    Article  PubMed  Google Scholar 

  99. Carde P, Hagenbeek A, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin’s disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1993;11(11):2258–72.

    PubMed  CAS  Google Scholar 

  100. Thomas J, Ferme C, et al. Results of the EORTC-GELA H9 Randomized Trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U Trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). Haematologica. 2007;92(s5):27.

    Google Scholar 

  101. Borchmann P, Diehl V, et al. Combined modality treatment with intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavourable Hodgkin lymphoma (HL): final analysis of the German Hodgkin Study Group (GHSG) HD11 Trial. ASH Annu Meet Abstr. 2009;114(22):717.

    Google Scholar 

  102. Advani R, Hoppe R, et al. Stage I/II Hodgkin’s disease (HD) with bulky mediastinal disease or other risk factors (RF); the Stanford V experience. Haematologica. 2007;92(s5):27.

    Google Scholar 

  103. Advani R, Maeda L, et al. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin’s disease. J Clin Oncol. 2007;25(25):3902–7.

    Article  PubMed  Google Scholar 

  104. Advani RH, Horning SJ. Treatment of early-stage Hodgkin’s disease. Semin Hematol. 1999;36(3):270–81.

    PubMed  CAS  Google Scholar 

  105. Horning S, Hoppe R, et al. Vinblastine, bleomycin and methotrexate: an effective adjuvant in favourable Hodgkin’s disease. J Clin Oncol. 1988;6:1822–31.

    PubMed  CAS  Google Scholar 

  106. Press OW, LeBlanc M, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. J Clin Oncol. 2001;19(22):4238–44.

    PubMed  CAS  Google Scholar 

  107. Nachman JB, Sposto R, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20(18):3765–71.

    Article  PubMed  Google Scholar 

  108. Meyer RM, Gospodarowicz MK, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(21):4634–42.

    Article  PubMed  CAS  Google Scholar 

  109. Straus DJ, Portlock CS, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104(12):3483–9.

    Article  PubMed  CAS  Google Scholar 

  110. Radford JA, O’Doherty M, et al. Results of the 2nd planned interim analysis of the RAPID trial (involved field radiotherapy versus no further treatment) in patients with clinical stages 1A and 2A Hodgkin lymphoma and a “negative” FDG-PET scan after 3 cycles ABVD. Blood. 2008;112:369s.

    Google Scholar 

  111. Josting A, Rudolph C, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol. 2002;13(10):1628–35.

    Article  PubMed  CAS  Google Scholar 

  112. Aparicio J, Segura A, et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol. 1999;10(5):593–5.

    Article  PubMed  CAS  Google Scholar 

  113. Moskowitz CH, Nimer SD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616–23.

    Article  PubMed  CAS  Google Scholar 

  114. Plunkett W, Huang P, et al. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996;23(5 Suppl 10):3–15.

    PubMed  CAS  Google Scholar 

  115. Friedberg JW, Neuberg D, et al. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer. 2003;98(5):978–82.

    Article  PubMed  CAS  Google Scholar 

  116. Sweetenham JW, Taghipour G, et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin’s disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1997;20(9):745–52.

    Article  PubMed  CAS  Google Scholar 

  117. Moskowitz CH, Yahalom J, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol. 148;890-897 2010.

    Google Scholar 

  118. Sweetenham JW, Carella AM, et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin’s disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol. 1999;17(10):3101–9.

    PubMed  CAS  Google Scholar 

  119. Bierman PJ, Bagin RG, et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s disease: long-term follow-up in 128 patients. Ann Oncol. 1993;4(9):767–73.

    PubMed  CAS  Google Scholar 

  120. Ansell SM, Horwitz SM, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25(19):2764–9.

    Article  PubMed  CAS  Google Scholar 

  121. Younes A, Romaguera J, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003;98(2):310–4.

    Article  PubMed  CAS  Google Scholar 

  122. Ekstrand BC, Lucas JB, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003;101(11):4285–9.

    Article  PubMed  CAS  Google Scholar 

  123. Younes A, Forero-Torres A, et al. Multiple complete responses in a phase 1 dose escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. Blood. 2008;112:s370.

    Google Scholar 

  124. Mendler JH, Kelly J, et al. Bortezomib and gemcitabine in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol. 2008;19(10):1759–64.

    Article  PubMed  CAS  Google Scholar 

  125. Younes A, Pro B, et al. Isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin lymphoma. Blood. 2007;110(11):2566.

    Google Scholar 

  126. Sutcliffe S, Wrigley PFM, et al. MVPP chemotherapy regimen for advanced Hodgkin’s disease. Br Med J. 1978;6114:679–83.

    Article  Google Scholar 

  127. Selby P, Patel P, et al. ChlVPP combination chemotherapy for Hodgkin’s disease: long-term results. Br J Cancer. 1990;62(2):279–85.

    Article  PubMed  CAS  Google Scholar 

  128. Viviani S, Bonadonna G, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results. J Clin Oncol. 1996;14(5):1421–30.

    PubMed  CAS  Google Scholar 

  129. Rodriguez J, Rodriguez MA, et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin’s disease. Blood. 1999;93(11):3632–6.

    PubMed  CAS  Google Scholar 

  130. Baetz T, Belch A, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2003;14(12):1762–7.

    Article  PubMed  CAS  Google Scholar 

  131. Brice P, Marolleau JP, Pautier P, Makke J, Cazals D, Dombret H, et al. Hematologic recovery and survival of lymphoma patients after autologous stem-cell transplantation: comparison of bone marrow and peripheral blood progenitor cells. Leukemia & lymphoma. 1996;22(5-6):449–56.

    Article  CAS  Google Scholar 

  132. Andre M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol. 1999;17(1):222–9.

    PubMed  CAS  Google Scholar 

  133. Ferme C, Mounier N, Divine M, Brice P, Stamatoullas A, Reman O, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin’s disease in relapse or failure after initial chemotherapy: results of the Groupe d’Etudes des Lymphomes de l’Adulte H89 Trial. J Clin Oncol. 2002;20(2):467–75.

    Article  PubMed  CAS  Google Scholar 

  134. Perz JB, Giles C, Szydlo R, O’Shea D, Sanz J, Chaidos A, et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin’s lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone marrow transplantation. 2007;39(1):41–7.

    Article  PubMed  CAS  Google Scholar 

  135. Johnson PWM, Sydes MR, Hancock BW, Cullen MH, Radford JA, Stenning SP. Consolidation radiotherapy in patients with advanced Hodgkin lymphoma: survival data from the UKLG LY09 randomised controlled trial (ISRCTN97144519). Journal of Clinical Oncology. 2010;in press.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut Gustave Roussy, F-94800, Villejuif, France

    Patrice Carde

  2. Southampton General Hospital, Southampton, UK

    Peter Johnson

Authors
  1. Patrice Carde
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Johnson .

Editor information

Editors and Affiliations

  1. Klinik I für Innere Medizin, Universität Köln, Joseph-Stelzmann-Str. 9, Köln, 50924, Germany

    Andreas Engert

  2. Dept. Medicine, Stanford University, Stanford, 94305-5479, California, USA

    Sandra J. Horning

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Carde, P., Johnson, P. (2011). Principles of Chemotherapy in Hodgkin Lymphoma. In: Engert, A., Horning, S. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12780-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-12780-9_9

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-12779-3

  • Online ISBN: 978-3-642-12780-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation